Experience rapid fat loss without stimulants with Burn2O
Never stop semaglutide without consulting your prescriber, as abrupt discontinuation may trigger other effects
Avoid rapid dose changes during illness or dehydration
Monitor for symptoms like upper abdominal pain, nausea, or jaundice, which may indicate gallbladder complications
Glycaemic outcomes In the primary analysis of the entire trial population (Table 2), the median (IQR) percentage TIR was 62% (5079%) at baseline and increased from 60% (5166%) at the end of usual care to 73% (6578%) at the end of the AID period, representing a mean difference of 13.7% (95% CI 9.8%, 17.6%)
The difference from placebo (95% CI) for semaglutide tablets 7 mg was -0.9 kg (-1.9, 0.1) and for semaglutide tablets 14 mg was -2.3 kg (-3.1, -1.5)